SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-004405
Filing Date
2022-01-14
Accepted
2022-01-14 16:00:54
Documents
12
Period of Report
2022-01-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm223005d1_8k.htm   iXBRL 8-K 24650
  Complete submission text file 0001104659-22-004405.txt   197142

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ettx-20220110.xsd EX-101.SCH 3036
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ettx-20220110_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ettx-20220110_pre.xml EX-101.PRE 22597
6 EXTRACTED XBRL INSTANCE DOCUMENT tm223005d1_8k_htm.xml XML 3601
Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Filer) CIK: 0001724344 (see all company filings)

IRS No.: 824592913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38670 | Film No.: 22531871
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences